whatshot

SRNE   $0.299  -23.33% Market Open

Sorrento Therapeutics Inc
show_chart Advanced Chart of SRNE
Last Events:

2023-03-29 Trend pattern changed from нисходящий клин to восходящий треугольник.

2023-03-29 Signal in Stochastic changed from bullish recovery to bearish. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: signal line crossed the middle level.

2023-03-29 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-03-29 Signal in RSI changed from bullish weakening to bearish recovery. RSI indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-03-29 Signal in EMA20 changed from bullish reversal to bearish reversal. 2023-02-08 the price crossed down the moving average line and formed a short-term downside trend.

2023-03-29 Trend changed from down and flat to flat and down.

2023-03-29 Trend pattern changed from восходящий треугольник to нисходящий клин.

2023-03-29 Signal in Stochastic changed from bearish to bullish recovery. The stochastic indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: main and signal line crossing.

Current temperature: 6.75
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.20
Target: 13.00
High with 48% probability: 1.54
Analyst Recommendations:
Number of estimates 1
Target Price Mean 13.00
Mean unverified/preliminary 13.00 / 13.00
Target Price Low / High 13.00 / 13.00
Median / STD DEV 13.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - Sell Sell
stoch Sell Sell -
ma20 Sell - -
ma50 - Sell -
ma100 - Sell -
Candlestick PatternFeb. 16, 2023 Deliberation Block Formation - consists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.
ISIN US83587F2020
ceo Dr. Henry H. Ji Ph.D.
Website https://www.sorrentotherapeutics.com
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.